Metadon Abcur

Methadone, the active ingredient in Metadon Abcur, is an opioid agonist presented as an oral tablet for oral use. It is employed in the management of opioid dependence and chronic pain, providing long‑acting analgesia and withdrawal suppression in adult patients.

GNH USA supplies Metadon Abcur as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring consistent, quality‑assured product availability across regulated markets and supporting patient‑care programs.

Methadone is used in opioid‑related pathways and pain management.

- Opioid dependence: suppresses withdrawal symptoms and supports maintenance therapy. - Chronic pain: provides long‑acting analgesia for severe, persistent pain. - Opioid detoxification: facilitates gradual tapering of opioid use during supervised detox programs.

Methadone may cause a range of adverse reactions, varying in frequency and severity.

Common Side Effects: - Constipation - Nausea - Drowsiness - Sweating

Serious or Rare Side Effects: - Respiratory depression - QT interval prolongation - Severe allergic reactions (anaphylaxis)

When prescribing or dispensing Metadon Abcur, consider the following precautions.

- Dose titration: adjust gradually under medical supervision to minimize withdrawal or overdose risk. - Cardiac monitoring: assess QT interval in patients with risk factors for arrhythmia. - Pregnancy: use only if benefit outweighs risk; classified Category C. - Breastfeeding: evaluate risk; methadone can be excreted in milk. - Drug dependence: monitor for signs of misuse or diversion. - Store at ambient temperature: keep below 25 °C, in original container, protected from moisture and light.

Methadone interacts with several medication classes; awareness helps prevent adverse events.

Major Interactions (Avoid): - Concurrent use with other CNS depressants (e.g., benzodiazepines) may cause profound respiratory depression. - Co‑administration with strong CYP3A4 inhibitors (e.g., ketoconazole) can increase methadone plasma levels. - Use with QT‑prolonging agents (e.g., haloperidol) raises risk of cardiac arrhythmia.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampin) may reduce methadone efficacy. - Certain antidepressants (e.g., SSRIs) may alter methadone metabolism. - Alcohol consumption can enhance sedative effects.